nodes	percent_of_prediction	percent_of_DWPC	metapath
Reboxetine—CYP3A4—prostate cancer	0.182	1	CbGaD
Reboxetine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0481	0.0948	CbGbCtD
Reboxetine—CYP2D6—Bicalutamide—prostate cancer	0.0397	0.0783	CbGbCtD
Reboxetine—ABCB1—Estramustine—prostate cancer	0.0392	0.0773	CbGbCtD
Reboxetine—CYP2D6—Abiraterone—prostate cancer	0.0329	0.0649	CbGbCtD
Reboxetine—ABCB1—Cabazitaxel—prostate cancer	0.0258	0.051	CbGbCtD
Reboxetine—CYP3A4—Bicalutamide—prostate cancer	0.0253	0.0498	CbGbCtD
Reboxetine—ABCB1—Estrone—prostate cancer	0.0253	0.0498	CbGbCtD
Reboxetine—CYP3A4—Estramustine—prostate cancer	0.0235	0.0463	CbGbCtD
Reboxetine—ABCB1—Ethinyl Estradiol—prostate cancer	0.0225	0.0444	CbGbCtD
Reboxetine—CYP3A4—Flutamide—prostate cancer	0.0209	0.0413	CbGbCtD
Reboxetine—CYP3A4—Abiraterone—prostate cancer	0.0209	0.0413	CbGbCtD
Reboxetine—ABCB1—Conjugated Estrogens—prostate cancer	0.0165	0.0326	CbGbCtD
Reboxetine—CYP3A4—Cabazitaxel—prostate cancer	0.0155	0.0305	CbGbCtD
Reboxetine—CYP3A4—Estrone—prostate cancer	0.0151	0.0298	CbGbCtD
Reboxetine—ABCB1—Mitoxantrone—prostate cancer	0.015	0.0296	CbGbCtD
Reboxetine—ABCB1—Estradiol—prostate cancer	0.0145	0.0286	CbGbCtD
Reboxetine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0135	0.0266	CbGbCtD
Reboxetine—ABCB1—Prednisone—prostate cancer	0.0125	0.0246	CbGbCtD
Reboxetine—CYP3A4—Conjugated Estrogens—prostate cancer	0.0099	0.0195	CbGbCtD
Reboxetine—ABCB1—Etoposide—prostate cancer	0.00947	0.0187	CbGbCtD
Reboxetine—CYP3A4—Mitoxantrone—prostate cancer	0.009	0.0177	CbGbCtD
Reboxetine—CYP3A4—Estradiol—prostate cancer	0.00869	0.0171	CbGbCtD
Reboxetine—ABCB1—Docetaxel—prostate cancer	0.00867	0.0171	CbGbCtD
Reboxetine—CYP3A4—Prednisone—prostate cancer	0.00748	0.0147	CbGbCtD
Reboxetine—ABCB1—Doxorubicin—prostate cancer	0.00646	0.0127	CbGbCtD
Reboxetine—CYP2D6—Doxorubicin—prostate cancer	0.00609	0.012	CbGbCtD
Reboxetine—CYP3A4—Etoposide—prostate cancer	0.00568	0.0112	CbGbCtD
Reboxetine—CYP3A4—Docetaxel—prostate cancer	0.00519	0.0102	CbGbCtD
Reboxetine—CYP3A4—Doxorubicin—prostate cancer	0.00387	0.00763	CbGbCtD
Reboxetine—Cyclizine—SULT1E1—prostate cancer	0.00229	0.593	CrCbGaD
Reboxetine—Diphenhydramine—CYP2C18—prostate cancer	0.000295	0.0767	CrCbGaD
Reboxetine—Benzatropine—CYP2C19—prostate cancer	0.000258	0.0668	CrCbGaD
Reboxetine—Diphenhydramine—SLC22A1—prostate cancer	0.000241	0.0626	CrCbGaD
Reboxetine—Phenprocoumon—CYP3A4—prostate cancer	0.000167	0.0433	CrCbGaD
Reboxetine—Atomoxetine—CYP2C19—prostate cancer	0.000164	0.0426	CrCbGaD
Reboxetine—Diphenhydramine—CYP2C19—prostate cancer	0.000132	0.0344	CrCbGaD
Reboxetine—Orphenadrine—CYP2E1—prostate cancer	0.000127	0.0328	CrCbGaD
Reboxetine—Atomoxetine—CYP3A4—prostate cancer	0.000104	0.0271	CrCbGaD
Reboxetine—Orphenadrine—CYP3A4—prostate cancer	7.97e-05	0.0207	CrCbGaD
Reboxetine—Ill-defined disorder—Prednisone—prostate cancer	6.25e-05	0.000271	CcSEcCtD
Reboxetine—Rash—Estradiol—prostate cancer	6.24e-05	0.000271	CcSEcCtD
Reboxetine—Infestation NOS—Doxorubicin—prostate cancer	6.24e-05	0.000271	CcSEcCtD
Reboxetine—Infestation—Doxorubicin—prostate cancer	6.24e-05	0.000271	CcSEcCtD
Reboxetine—Dermatitis—Estradiol—prostate cancer	6.24e-05	0.000271	CcSEcCtD
Reboxetine—Anaemia—Prednisone—prostate cancer	6.23e-05	0.00027	CcSEcCtD
Reboxetine—Confusional state—Capecitabine—prostate cancer	6.23e-05	0.00027	CcSEcCtD
Reboxetine—Tachycardia—Docetaxel—prostate cancer	6.23e-05	0.00027	CcSEcCtD
Reboxetine—Headache—Estradiol—prostate cancer	6.2e-05	0.000269	CcSEcCtD
Reboxetine—Skin disorder—Docetaxel—prostate cancer	6.2e-05	0.000269	CcSEcCtD
Reboxetine—Agitation—Prednisone—prostate cancer	6.19e-05	0.000269	CcSEcCtD
Reboxetine—Bradycardia—Epirubicin—prostate cancer	6.17e-05	0.000267	CcSEcCtD
Reboxetine—Infection—Capecitabine—prostate cancer	6.14e-05	0.000266	CcSEcCtD
Reboxetine—Urticaria—Etoposide—prostate cancer	6.1e-05	0.000265	CcSEcCtD
Reboxetine—Anorexia—Docetaxel—prostate cancer	6.08e-05	0.000264	CcSEcCtD
Reboxetine—Malaise—Prednisone—prostate cancer	6.08e-05	0.000264	CcSEcCtD
Reboxetine—Shock—Capecitabine—prostate cancer	6.08e-05	0.000264	CcSEcCtD
Reboxetine—Rhinitis—Epirubicin—prostate cancer	6.07e-05	0.000263	CcSEcCtD
Reboxetine—Abdominal pain—Etoposide—prostate cancer	6.07e-05	0.000263	CcSEcCtD
Reboxetine—Body temperature increased—Etoposide—prostate cancer	6.07e-05	0.000263	CcSEcCtD
Reboxetine—Urinary tract infection—Doxorubicin—prostate cancer	6.07e-05	0.000263	CcSEcCtD
Reboxetine—Conjunctivitis—Doxorubicin—prostate cancer	6.07e-05	0.000263	CcSEcCtD
Reboxetine—Nervous system disorder—Capecitabine—prostate cancer	6.06e-05	0.000263	CcSEcCtD
Reboxetine—Vertigo—Prednisone—prostate cancer	6.06e-05	0.000263	CcSEcCtD
Reboxetine—Syncope—Prednisone—prostate cancer	6.05e-05	0.000262	CcSEcCtD
Reboxetine—Tachycardia—Capecitabine—prostate cancer	6.03e-05	0.000262	CcSEcCtD
Reboxetine—Pharyngitis—Epirubicin—prostate cancer	6.01e-05	0.000261	CcSEcCtD
Reboxetine—Skin disorder—Capecitabine—prostate cancer	6e-05	0.00026	CcSEcCtD
Reboxetine—Sweating—Doxorubicin—prostate cancer	5.98e-05	0.00026	CcSEcCtD
Reboxetine—Urinary tract disorder—Epirubicin—prostate cancer	5.98e-05	0.000259	CcSEcCtD
Reboxetine—Hyperhidrosis—Capecitabine—prostate cancer	5.97e-05	0.000259	CcSEcCtD
Reboxetine—Hypotension—Docetaxel—prostate cancer	5.96e-05	0.000259	CcSEcCtD
Reboxetine—Connective tissue disorder—Epirubicin—prostate cancer	5.95e-05	0.000258	CcSEcCtD
Reboxetine—Urethral disorder—Epirubicin—prostate cancer	5.94e-05	0.000258	CcSEcCtD
Reboxetine—Loss of consciousness—Prednisone—prostate cancer	5.92e-05	0.000257	CcSEcCtD
Reboxetine—Epistaxis—Doxorubicin—prostate cancer	5.89e-05	0.000255	CcSEcCtD
Reboxetine—Anorexia—Capecitabine—prostate cancer	5.89e-05	0.000255	CcSEcCtD
Reboxetine—Nausea—Estradiol—prostate cancer	5.88e-05	0.000255	CcSEcCtD
Reboxetine—Vomiting—Mitoxantrone—prostate cancer	5.87e-05	0.000255	CcSEcCtD
Reboxetine—Sinusitis—Doxorubicin—prostate cancer	5.86e-05	0.000254	CcSEcCtD
Reboxetine—Visual impairment—Epirubicin—prostate cancer	5.84e-05	0.000253	CcSEcCtD
Reboxetine—Hypertension—Prednisone—prostate cancer	5.82e-05	0.000252	CcSEcCtD
Reboxetine—Rash—Mitoxantrone—prostate cancer	5.82e-05	0.000252	CcSEcCtD
Reboxetine—Dermatitis—Mitoxantrone—prostate cancer	5.81e-05	0.000252	CcSEcCtD
Reboxetine—Headache—Mitoxantrone—prostate cancer	5.78e-05	0.000251	CcSEcCtD
Reboxetine—Hypotension—Capecitabine—prostate cancer	5.77e-05	0.00025	CcSEcCtD
Reboxetine—Insomnia—Docetaxel—prostate cancer	5.77e-05	0.00025	CcSEcCtD
Reboxetine—Paraesthesia—Docetaxel—prostate cancer	5.73e-05	0.000249	CcSEcCtD
Reboxetine—Anxiety—Prednisone—prostate cancer	5.72e-05	0.000248	CcSEcCtD
Reboxetine—Bradycardia—Doxorubicin—prostate cancer	5.7e-05	0.000248	CcSEcCtD
Reboxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	5.7e-05	0.000247	CcSEcCtD
Reboxetine—Dyspnoea—Docetaxel—prostate cancer	5.69e-05	0.000247	CcSEcCtD
Reboxetine—Somnolence—Docetaxel—prostate cancer	5.67e-05	0.000246	CcSEcCtD
Reboxetine—Discomfort—Prednisone—prostate cancer	5.67e-05	0.000246	CcSEcCtD
Reboxetine—Eye disorder—Epirubicin—prostate cancer	5.66e-05	0.000246	CcSEcCtD
Reboxetine—Hypersensitivity—Etoposide—prostate cancer	5.66e-05	0.000245	CcSEcCtD
Reboxetine—Tinnitus—Epirubicin—prostate cancer	5.65e-05	0.000245	CcSEcCtD
Reboxetine—Cardiac disorder—Epirubicin—prostate cancer	5.62e-05	0.000244	CcSEcCtD
Reboxetine—Rhinitis—Doxorubicin—prostate cancer	5.62e-05	0.000244	CcSEcCtD
Reboxetine—Dyspepsia—Docetaxel—prostate cancer	5.62e-05	0.000244	CcSEcCtD
Reboxetine—Insomnia—Capecitabine—prostate cancer	5.59e-05	0.000242	CcSEcCtD
Reboxetine—Pharyngitis—Doxorubicin—prostate cancer	5.56e-05	0.000241	CcSEcCtD
Reboxetine—Paraesthesia—Capecitabine—prostate cancer	5.55e-05	0.000241	CcSEcCtD
Reboxetine—Decreased appetite—Docetaxel—prostate cancer	5.55e-05	0.000241	CcSEcCtD
Reboxetine—Urinary tract disorder—Doxorubicin—prostate cancer	5.53e-05	0.00024	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Docetaxel—prostate cancer	5.51e-05	0.000239	CcSEcCtD
Reboxetine—Asthenia—Etoposide—prostate cancer	5.51e-05	0.000239	CcSEcCtD
Reboxetine—Connective tissue disorder—Doxorubicin—prostate cancer	5.51e-05	0.000239	CcSEcCtD
Reboxetine—Dyspnoea—Capecitabine—prostate cancer	5.51e-05	0.000239	CcSEcCtD
Reboxetine—Angiopathy—Epirubicin—prostate cancer	5.49e-05	0.000238	CcSEcCtD
Reboxetine—Urethral disorder—Doxorubicin—prostate cancer	5.49e-05	0.000238	CcSEcCtD
Reboxetine—Nausea—Mitoxantrone—prostate cancer	5.48e-05	0.000238	CcSEcCtD
Reboxetine—Immune system disorder—Epirubicin—prostate cancer	5.47e-05	0.000237	CcSEcCtD
Reboxetine—Infection—Prednisone—prostate cancer	5.47e-05	0.000237	CcSEcCtD
Reboxetine—Mediastinal disorder—Epirubicin—prostate cancer	5.46e-05	0.000237	CcSEcCtD
Reboxetine—Constipation—Docetaxel—prostate cancer	5.46e-05	0.000237	CcSEcCtD
Reboxetine—Dyspepsia—Capecitabine—prostate cancer	5.44e-05	0.000236	CcSEcCtD
Reboxetine—Chills—Epirubicin—prostate cancer	5.43e-05	0.000236	CcSEcCtD
Reboxetine—Shock—Prednisone—prostate cancer	5.41e-05	0.000235	CcSEcCtD
Reboxetine—Visual impairment—Doxorubicin—prostate cancer	5.4e-05	0.000234	CcSEcCtD
Reboxetine—Nervous system disorder—Prednisone—prostate cancer	5.4e-05	0.000234	CcSEcCtD
Reboxetine—Tachycardia—Prednisone—prostate cancer	5.37e-05	0.000233	CcSEcCtD
Reboxetine—Decreased appetite—Capecitabine—prostate cancer	5.37e-05	0.000233	CcSEcCtD
Reboxetine—Skin disorder—Prednisone—prostate cancer	5.34e-05	0.000232	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Capecitabine—prostate cancer	5.33e-05	0.000231	CcSEcCtD
Reboxetine—Hyperhidrosis—Prednisone—prostate cancer	5.32e-05	0.000231	CcSEcCtD
Reboxetine—Mental disorder—Epirubicin—prostate cancer	5.31e-05	0.00023	CcSEcCtD
Reboxetine—Constipation—Capecitabine—prostate cancer	5.28e-05	0.000229	CcSEcCtD
Reboxetine—Malnutrition—Epirubicin—prostate cancer	5.27e-05	0.000229	CcSEcCtD
Reboxetine—Feeling abnormal—Docetaxel—prostate cancer	5.26e-05	0.000228	CcSEcCtD
Reboxetine—Diarrhoea—Etoposide—prostate cancer	5.25e-05	0.000228	CcSEcCtD
Reboxetine—Anorexia—Prednisone—prostate cancer	5.24e-05	0.000228	CcSEcCtD
Reboxetine—Eye disorder—Doxorubicin—prostate cancer	5.24e-05	0.000227	CcSEcCtD
Reboxetine—Tinnitus—Doxorubicin—prostate cancer	5.22e-05	0.000227	CcSEcCtD
Reboxetine—Gastrointestinal pain—Docetaxel—prostate cancer	5.22e-05	0.000226	CcSEcCtD
Reboxetine—Cardiac disorder—Doxorubicin—prostate cancer	5.2e-05	0.000226	CcSEcCtD
Reboxetine—Tension—Epirubicin—prostate cancer	5.17e-05	0.000224	CcSEcCtD
Reboxetine—Dysgeusia—Epirubicin—prostate cancer	5.16e-05	0.000224	CcSEcCtD
Reboxetine—Nervousness—Epirubicin—prostate cancer	5.12e-05	0.000222	CcSEcCtD
Reboxetine—Feeling abnormal—Capecitabine—prostate cancer	5.09e-05	0.000221	CcSEcCtD
Reboxetine—Angiopathy—Doxorubicin—prostate cancer	5.08e-05	0.000221	CcSEcCtD
Reboxetine—Dizziness—Etoposide—prostate cancer	5.08e-05	0.00022	CcSEcCtD
Reboxetine—Immune system disorder—Doxorubicin—prostate cancer	5.06e-05	0.00022	CcSEcCtD
Reboxetine—Gastrointestinal pain—Capecitabine—prostate cancer	5.05e-05	0.000219	CcSEcCtD
Reboxetine—Mediastinal disorder—Doxorubicin—prostate cancer	5.05e-05	0.000219	CcSEcCtD
Reboxetine—Body temperature increased—Docetaxel—prostate cancer	5.04e-05	0.000219	CcSEcCtD
Reboxetine—Abdominal pain—Docetaxel—prostate cancer	5.04e-05	0.000219	CcSEcCtD
Reboxetine—Chills—Doxorubicin—prostate cancer	5.03e-05	0.000218	CcSEcCtD
Reboxetine—Insomnia—Prednisone—prostate cancer	4.98e-05	0.000216	CcSEcCtD
Reboxetine—Paraesthesia—Prednisone—prostate cancer	4.94e-05	0.000214	CcSEcCtD
Reboxetine—Mental disorder—Doxorubicin—prostate cancer	4.91e-05	0.000213	CcSEcCtD
Reboxetine—Urticaria—Capecitabine—prostate cancer	4.91e-05	0.000213	CcSEcCtD
Reboxetine—Ill-defined disorder—Epirubicin—prostate cancer	4.89e-05	0.000212	CcSEcCtD
Reboxetine—Abdominal pain—Capecitabine—prostate cancer	4.88e-05	0.000212	CcSEcCtD
Reboxetine—Body temperature increased—Capecitabine—prostate cancer	4.88e-05	0.000212	CcSEcCtD
Reboxetine—Vomiting—Etoposide—prostate cancer	4.88e-05	0.000212	CcSEcCtD
Reboxetine—Malnutrition—Doxorubicin—prostate cancer	4.88e-05	0.000212	CcSEcCtD
Reboxetine—Anaemia—Epirubicin—prostate cancer	4.87e-05	0.000211	CcSEcCtD
Reboxetine—Agitation—Epirubicin—prostate cancer	4.84e-05	0.00021	CcSEcCtD
Reboxetine—Dyspepsia—Prednisone—prostate cancer	4.84e-05	0.00021	CcSEcCtD
Reboxetine—Rash—Etoposide—prostate cancer	4.84e-05	0.00021	CcSEcCtD
Reboxetine—Dermatitis—Etoposide—prostate cancer	4.84e-05	0.00021	CcSEcCtD
Reboxetine—Headache—Etoposide—prostate cancer	4.81e-05	0.000209	CcSEcCtD
Reboxetine—Tension—Doxorubicin—prostate cancer	4.79e-05	0.000208	CcSEcCtD
Reboxetine—Decreased appetite—Prednisone—prostate cancer	4.78e-05	0.000207	CcSEcCtD
Reboxetine—Dysgeusia—Doxorubicin—prostate cancer	4.78e-05	0.000207	CcSEcCtD
Reboxetine—Malaise—Epirubicin—prostate cancer	4.75e-05	0.000206	CcSEcCtD
Reboxetine—Nervousness—Doxorubicin—prostate cancer	4.74e-05	0.000206	CcSEcCtD
Reboxetine—Vertigo—Epirubicin—prostate cancer	4.74e-05	0.000206	CcSEcCtD
Reboxetine—Syncope—Epirubicin—prostate cancer	4.73e-05	0.000205	CcSEcCtD
Reboxetine—Leukopenia—Epirubicin—prostate cancer	4.72e-05	0.000205	CcSEcCtD
Reboxetine—Constipation—Prednisone—prostate cancer	4.7e-05	0.000204	CcSEcCtD
Reboxetine—Hypersensitivity—Docetaxel—prostate cancer	4.7e-05	0.000204	CcSEcCtD
Reboxetine—Palpitations—Epirubicin—prostate cancer	4.66e-05	0.000202	CcSEcCtD
Reboxetine—Loss of consciousness—Epirubicin—prostate cancer	4.63e-05	0.000201	CcSEcCtD
Reboxetine—Asthenia—Docetaxel—prostate cancer	4.58e-05	0.000199	CcSEcCtD
Reboxetine—Nausea—Etoposide—prostate cancer	4.56e-05	0.000198	CcSEcCtD
Reboxetine—Hypertension—Epirubicin—prostate cancer	4.55e-05	0.000197	CcSEcCtD
Reboxetine—Hypersensitivity—Capecitabine—prostate cancer	4.55e-05	0.000197	CcSEcCtD
Reboxetine—Feeling abnormal—Prednisone—prostate cancer	4.53e-05	0.000197	CcSEcCtD
Reboxetine—Ill-defined disorder—Doxorubicin—prostate cancer	4.53e-05	0.000196	CcSEcCtD
Reboxetine—Anaemia—Doxorubicin—prostate cancer	4.51e-05	0.000196	CcSEcCtD
Reboxetine—Gastrointestinal pain—Prednisone—prostate cancer	4.5e-05	0.000195	CcSEcCtD
Reboxetine—Chest pain—Epirubicin—prostate cancer	4.49e-05	0.000195	CcSEcCtD
Reboxetine—Agitation—Doxorubicin—prostate cancer	4.48e-05	0.000194	CcSEcCtD
Reboxetine—Anxiety—Epirubicin—prostate cancer	4.47e-05	0.000194	CcSEcCtD
Reboxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	4.46e-05	0.000193	CcSEcCtD
Reboxetine—Discomfort—Epirubicin—prostate cancer	4.43e-05	0.000192	CcSEcCtD
Reboxetine—Asthenia—Capecitabine—prostate cancer	4.43e-05	0.000192	CcSEcCtD
Reboxetine—Malaise—Doxorubicin—prostate cancer	4.4e-05	0.000191	CcSEcCtD
Reboxetine—Dry mouth—Epirubicin—prostate cancer	4.39e-05	0.00019	CcSEcCtD
Reboxetine—Vertigo—Doxorubicin—prostate cancer	4.38e-05	0.00019	CcSEcCtD
Reboxetine—Syncope—Doxorubicin—prostate cancer	4.37e-05	0.00019	CcSEcCtD
Reboxetine—Urticaria—Prednisone—prostate cancer	4.37e-05	0.00019	CcSEcCtD
Reboxetine—Leukopenia—Doxorubicin—prostate cancer	4.37e-05	0.000189	CcSEcCtD
Reboxetine—Diarrhoea—Docetaxel—prostate cancer	4.36e-05	0.000189	CcSEcCtD
Reboxetine—Body temperature increased—Prednisone—prostate cancer	4.35e-05	0.000189	CcSEcCtD
Reboxetine—Abdominal pain—Prednisone—prostate cancer	4.35e-05	0.000189	CcSEcCtD
Reboxetine—Confusional state—Epirubicin—prostate cancer	4.34e-05	0.000188	CcSEcCtD
Reboxetine—Palpitations—Doxorubicin—prostate cancer	4.31e-05	0.000187	CcSEcCtD
Reboxetine—Loss of consciousness—Doxorubicin—prostate cancer	4.29e-05	0.000186	CcSEcCtD
Reboxetine—Infection—Epirubicin—prostate cancer	4.27e-05	0.000185	CcSEcCtD
Reboxetine—Shock—Epirubicin—prostate cancer	4.23e-05	0.000184	CcSEcCtD
Reboxetine—Diarrhoea—Capecitabine—prostate cancer	4.23e-05	0.000183	CcSEcCtD
Reboxetine—Nervous system disorder—Epirubicin—prostate cancer	4.22e-05	0.000183	CcSEcCtD
Reboxetine—Dizziness—Docetaxel—prostate cancer	4.22e-05	0.000183	CcSEcCtD
Reboxetine—Hypertension—Doxorubicin—prostate cancer	4.21e-05	0.000183	CcSEcCtD
Reboxetine—Tachycardia—Epirubicin—prostate cancer	4.2e-05	0.000182	CcSEcCtD
Reboxetine—Skin disorder—Epirubicin—prostate cancer	4.18e-05	0.000181	CcSEcCtD
Reboxetine—Hyperhidrosis—Epirubicin—prostate cancer	4.16e-05	0.00018	CcSEcCtD
Reboxetine—Chest pain—Doxorubicin—prostate cancer	4.15e-05	0.00018	CcSEcCtD
Reboxetine—Anxiety—Doxorubicin—prostate cancer	4.14e-05	0.00018	CcSEcCtD
Reboxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	4.12e-05	0.000179	CcSEcCtD
Reboxetine—Discomfort—Doxorubicin—prostate cancer	4.1e-05	0.000178	CcSEcCtD
Reboxetine—Anorexia—Epirubicin—prostate cancer	4.1e-05	0.000178	CcSEcCtD
Reboxetine—Dizziness—Capecitabine—prostate cancer	4.08e-05	0.000177	CcSEcCtD
Reboxetine—Dry mouth—Doxorubicin—prostate cancer	4.06e-05	0.000176	CcSEcCtD
Reboxetine—Vomiting—Docetaxel—prostate cancer	4.06e-05	0.000176	CcSEcCtD
Reboxetine—Hypersensitivity—Prednisone—prostate cancer	4.05e-05	0.000176	CcSEcCtD
Reboxetine—Rash—Docetaxel—prostate cancer	4.02e-05	0.000175	CcSEcCtD
Reboxetine—Hypotension—Epirubicin—prostate cancer	4.02e-05	0.000174	CcSEcCtD
Reboxetine—Dermatitis—Docetaxel—prostate cancer	4.02e-05	0.000174	CcSEcCtD
Reboxetine—Confusional state—Doxorubicin—prostate cancer	4.01e-05	0.000174	CcSEcCtD
Reboxetine—Headache—Docetaxel—prostate cancer	4e-05	0.000173	CcSEcCtD
Reboxetine—Infection—Doxorubicin—prostate cancer	3.96e-05	0.000172	CcSEcCtD
Reboxetine—Asthenia—Prednisone—prostate cancer	3.95e-05	0.000171	CcSEcCtD
Reboxetine—Vomiting—Capecitabine—prostate cancer	3.93e-05	0.00017	CcSEcCtD
Reboxetine—Shock—Doxorubicin—prostate cancer	3.92e-05	0.00017	CcSEcCtD
Reboxetine—Nervous system disorder—Doxorubicin—prostate cancer	3.9e-05	0.000169	CcSEcCtD
Reboxetine—Rash—Capecitabine—prostate cancer	3.89e-05	0.000169	CcSEcCtD
Reboxetine—Insomnia—Epirubicin—prostate cancer	3.89e-05	0.000169	CcSEcCtD
Reboxetine—Dermatitis—Capecitabine—prostate cancer	3.89e-05	0.000169	CcSEcCtD
Reboxetine—Tachycardia—Doxorubicin—prostate cancer	3.89e-05	0.000169	CcSEcCtD
Reboxetine—Headache—Capecitabine—prostate cancer	3.87e-05	0.000168	CcSEcCtD
Reboxetine—Skin disorder—Doxorubicin—prostate cancer	3.87e-05	0.000168	CcSEcCtD
Reboxetine—Paraesthesia—Epirubicin—prostate cancer	3.86e-05	0.000168	CcSEcCtD
Reboxetine—Hyperhidrosis—Doxorubicin—prostate cancer	3.85e-05	0.000167	CcSEcCtD
Reboxetine—Dyspnoea—Epirubicin—prostate cancer	3.84e-05	0.000166	CcSEcCtD
Reboxetine—Somnolence—Epirubicin—prostate cancer	3.83e-05	0.000166	CcSEcCtD
Reboxetine—Anorexia—Doxorubicin—prostate cancer	3.79e-05	0.000165	CcSEcCtD
Reboxetine—Nausea—Docetaxel—prostate cancer	3.79e-05	0.000164	CcSEcCtD
Reboxetine—Dyspepsia—Epirubicin—prostate cancer	3.79e-05	0.000164	CcSEcCtD
Reboxetine—Diarrhoea—Prednisone—prostate cancer	3.76e-05	0.000163	CcSEcCtD
Reboxetine—Decreased appetite—Epirubicin—prostate cancer	3.74e-05	0.000162	CcSEcCtD
Reboxetine—Hypotension—Doxorubicin—prostate cancer	3.72e-05	0.000161	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Epirubicin—prostate cancer	3.71e-05	0.000161	CcSEcCtD
Reboxetine—Constipation—Epirubicin—prostate cancer	3.68e-05	0.00016	CcSEcCtD
Reboxetine—Nausea—Capecitabine—prostate cancer	3.67e-05	0.000159	CcSEcCtD
Reboxetine—Dizziness—Prednisone—prostate cancer	3.64e-05	0.000158	CcSEcCtD
Reboxetine—Insomnia—Doxorubicin—prostate cancer	3.6e-05	0.000156	CcSEcCtD
Reboxetine—Paraesthesia—Doxorubicin—prostate cancer	3.57e-05	0.000155	CcSEcCtD
Reboxetine—Dyspnoea—Doxorubicin—prostate cancer	3.55e-05	0.000154	CcSEcCtD
Reboxetine—Feeling abnormal—Epirubicin—prostate cancer	3.55e-05	0.000154	CcSEcCtD
Reboxetine—Somnolence—Doxorubicin—prostate cancer	3.54e-05	0.000154	CcSEcCtD
Reboxetine—Gastrointestinal pain—Epirubicin—prostate cancer	3.52e-05	0.000153	CcSEcCtD
Reboxetine—Dyspepsia—Doxorubicin—prostate cancer	3.5e-05	0.000152	CcSEcCtD
Reboxetine—Vomiting—Prednisone—prostate cancer	3.5e-05	0.000152	CcSEcCtD
Reboxetine—Rash—Prednisone—prostate cancer	3.47e-05	0.00015	CcSEcCtD
Reboxetine—Dermatitis—Prednisone—prostate cancer	3.47e-05	0.00015	CcSEcCtD
Reboxetine—Decreased appetite—Doxorubicin—prostate cancer	3.46e-05	0.00015	CcSEcCtD
Reboxetine—Headache—Prednisone—prostate cancer	3.45e-05	0.00015	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.44e-05	0.000149	CcSEcCtD
Reboxetine—Urticaria—Epirubicin—prostate cancer	3.42e-05	0.000148	CcSEcCtD
Reboxetine—Constipation—Doxorubicin—prostate cancer	3.4e-05	0.000148	CcSEcCtD
Reboxetine—Abdominal pain—Epirubicin—prostate cancer	3.4e-05	0.000148	CcSEcCtD
Reboxetine—Body temperature increased—Epirubicin—prostate cancer	3.4e-05	0.000148	CcSEcCtD
Reboxetine—Feeling abnormal—Doxorubicin—prostate cancer	3.28e-05	0.000142	CcSEcCtD
Reboxetine—Nausea—Prednisone—prostate cancer	3.27e-05	0.000142	CcSEcCtD
Reboxetine—Gastrointestinal pain—Doxorubicin—prostate cancer	3.26e-05	0.000141	CcSEcCtD
Reboxetine—Hypersensitivity—Epirubicin—prostate cancer	3.17e-05	0.000138	CcSEcCtD
Reboxetine—Urticaria—Doxorubicin—prostate cancer	3.16e-05	0.000137	CcSEcCtD
Reboxetine—Body temperature increased—Doxorubicin—prostate cancer	3.15e-05	0.000137	CcSEcCtD
Reboxetine—Abdominal pain—Doxorubicin—prostate cancer	3.15e-05	0.000137	CcSEcCtD
Reboxetine—Asthenia—Epirubicin—prostate cancer	3.09e-05	0.000134	CcSEcCtD
Reboxetine—Diarrhoea—Epirubicin—prostate cancer	2.94e-05	0.000128	CcSEcCtD
Reboxetine—Hypersensitivity—Doxorubicin—prostate cancer	2.93e-05	0.000127	CcSEcCtD
Reboxetine—Asthenia—Doxorubicin—prostate cancer	2.86e-05	0.000124	CcSEcCtD
Reboxetine—Dizziness—Epirubicin—prostate cancer	2.85e-05	0.000123	CcSEcCtD
Reboxetine—Vomiting—Epirubicin—prostate cancer	2.74e-05	0.000119	CcSEcCtD
Reboxetine—Diarrhoea—Doxorubicin—prostate cancer	2.72e-05	0.000118	CcSEcCtD
Reboxetine—Rash—Epirubicin—prostate cancer	2.71e-05	0.000118	CcSEcCtD
Reboxetine—Dermatitis—Epirubicin—prostate cancer	2.71e-05	0.000118	CcSEcCtD
Reboxetine—Headache—Epirubicin—prostate cancer	2.7e-05	0.000117	CcSEcCtD
Reboxetine—Dizziness—Doxorubicin—prostate cancer	2.63e-05	0.000114	CcSEcCtD
Reboxetine—Nausea—Epirubicin—prostate cancer	2.56e-05	0.000111	CcSEcCtD
Reboxetine—Vomiting—Doxorubicin—prostate cancer	2.53e-05	0.00011	CcSEcCtD
Reboxetine—Rash—Doxorubicin—prostate cancer	2.51e-05	0.000109	CcSEcCtD
Reboxetine—Dermatitis—Doxorubicin—prostate cancer	2.51e-05	0.000109	CcSEcCtD
Reboxetine—Headache—Doxorubicin—prostate cancer	2.49e-05	0.000108	CcSEcCtD
Reboxetine—Nausea—Doxorubicin—prostate cancer	2.36e-05	0.000103	CcSEcCtD
Reboxetine—HTR2C—Signaling Pathways—PRKCQ—prostate cancer	9.33e-06	0.000122	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—NGFR—prostate cancer	9.33e-06	0.000122	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—LRP2—prostate cancer	9.26e-06	0.000121	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PLCB2—prostate cancer	9.26e-06	0.000121	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CYP2C18—prostate cancer	9.26e-06	0.000121	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—MAP3K7—prostate cancer	9.21e-06	0.00012	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—TNFRSF21—prostate cancer	9.21e-06	0.00012	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—SULT2A1—prostate cancer	9.13e-06	0.000119	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	9.13e-06	0.000119	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—P4HB—prostate cancer	9.08e-06	0.000118	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—MED12—prostate cancer	8.98e-06	0.000117	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYP7B1—prostate cancer	8.96e-06	0.000117	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—MTAP—prostate cancer	8.96e-06	0.000117	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GNG5—prostate cancer	8.91e-06	0.000116	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—FGF10—prostate cancer	8.86e-06	0.000116	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—SLC22A1—prostate cancer	8.83e-06	0.000115	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—ADRB2—prostate cancer	8.77e-06	0.000114	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—SULT1E1—prostate cancer	8.73e-06	0.000114	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—SRD5A1—prostate cancer	8.73e-06	0.000114	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—JAK2—prostate cancer	8.65e-06	0.000113	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—MAP2K1—prostate cancer	8.61e-06	0.000112	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—SULT2A1—prostate cancer	8.6e-06	0.000112	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—NCOA3—prostate cancer	8.59e-06	0.000112	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—PIK3CD—prostate cancer	8.56e-06	0.000112	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—VAV3—prostate cancer	8.55e-06	0.000112	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—MED12—prostate cancer	8.47e-06	0.00011	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—TGFBR2—prostate cancer	8.43e-06	0.00011	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GNG5—prostate cancer	8.4e-06	0.00011	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—ACSL4—prostate cancer	8.33e-06	0.000109	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—HSD17B3—prostate cancer	8.33e-06	0.000109	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—ITPR1—prostate cancer	8.29e-06	0.000108	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—PIK3CB—prostate cancer	8.21e-06	0.000107	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—HPGDS—prostate cancer	8.19e-06	0.000107	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CYP2C19—prostate cancer	8.14e-06	0.000106	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—NCOA3—prostate cancer	8.09e-06	0.000106	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—ARG2—prostate cancer	7.98e-06	0.000104	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PHGDH—prostate cancer	7.98e-06	0.000104	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—UMPS—prostate cancer	7.98e-06	0.000104	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTT1—prostate cancer	7.94e-06	0.000104	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—ACHE—prostate cancer	7.94e-06	0.000104	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—IGF1R—prostate cancer	7.93e-06	0.000103	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—CXCL8—prostate cancer	7.89e-06	0.000103	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—JAK2—prostate cancer	7.85e-06	0.000102	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CYP2A6—prostate cancer	7.85e-06	0.000102	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—LDHB—prostate cancer	7.83e-06	0.000102	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—HPGDS—prostate cancer	7.72e-06	0.000101	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	7.71e-06	0.000101	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYP3A5—prostate cancer	7.69e-06	0.0001	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CYP2C19—prostate cancer	7.67e-06	0.0001	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—AKR1C3—prostate cancer	7.64e-06	9.97e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—LPL—prostate cancer	7.6e-06	9.92e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PRKACB—prostate cancer	7.6e-06	9.92e-05	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—IL2—prostate cancer	7.54e-06	9.84e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—PDGFRB—prostate cancer	7.53e-06	9.83e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CYP17A1—prostate cancer	7.52e-06	9.81e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTT1—prostate cancer	7.49e-06	9.77e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—ACHE—prostate cancer	7.49e-06	9.77e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—PIK3CB—prostate cancer	7.46e-06	9.73e-05	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	7.44e-06	9.71e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTA3—prostate cancer	7.42e-06	9.69e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—UCP3—prostate cancer	7.42e-06	9.69e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—TCN2—prostate cancer	7.42e-06	9.69e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PDHA1—prostate cancer	7.42e-06	9.69e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CYP2A6—prostate cancer	7.4e-06	9.66e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—ITGB3—prostate cancer	7.34e-06	9.58e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—AKR1C3—prostate cancer	7.2e-06	9.39e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—CXCL8—prostate cancer	7.17e-06	9.35e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—NCOA2—prostate cancer	7.17e-06	9.35e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PRKACB—prostate cancer	7.16e-06	9.34e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—ERBB3—prostate cancer	7.12e-06	9.29e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—FGFR2—prostate cancer	7.11e-06	9.28e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CYP17A1—prostate cancer	7.09e-06	9.25e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—SLC22A3—prostate cancer	7.08e-06	9.24e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—HSD3B1—prostate cancer	7.08e-06	9.24e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—IL2—prostate cancer	6.85e-06	8.94e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—SLC5A5—prostate cancer	6.84e-06	8.92e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—TERT—prostate cancer	6.83e-06	8.91e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—TBXAS1—prostate cancer	6.79e-06	8.86e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTA4—prostate cancer	6.79e-06	8.86e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—NCOA2—prostate cancer	6.75e-06	8.81e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CYP2E1—prostate cancer	6.68e-06	8.71e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTA2—prostate cancer	6.62e-06	8.63e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—NQO1—prostate cancer	6.6e-06	8.62e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—ABCG5—prostate cancer	6.54e-06	8.53e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—SULT1A1—prostate cancer	6.54e-06	8.53e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—HIF1A—prostate cancer	6.53e-06	8.52e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—TH—prostate cancer	6.51e-06	8.49e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—SLC5A5—prostate cancer	6.44e-06	8.41e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CYP3A4—prostate cancer	6.44e-06	8.4e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTA1—prostate cancer	6.38e-06	8.33e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—LEP—prostate cancer	6.37e-06	8.32e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CYP1B1—prostate cancer	6.33e-06	8.26e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CAV1—prostate cancer	6.31e-06	8.24e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTO1—prostate cancer	6.31e-06	8.24e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—NAT2—prostate cancer	6.31e-06	8.24e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—HSD3B2—prostate cancer	6.31e-06	8.24e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CYP2E1—prostate cancer	6.29e-06	8.21e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—KDR—prostate cancer	6.24e-06	8.15e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—NQO1—prostate cancer	6.22e-06	8.12e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—TH—prostate cancer	6.13e-06	8e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GGT1—prostate cancer	6.13e-06	8e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—ESR1—prostate cancer	6.08e-06	7.94e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CYP3A4—prostate cancer	6.07e-06	7.92e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PLCB2—prostate cancer	6.05e-06	7.9e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—LRP2—prostate cancer	6.05e-06	7.9e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYP2C18—prostate cancer	6.05e-06	7.9e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—NCOA1—prostate cancer	6.04e-06	7.88e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CYP1B1—prostate cancer	5.96e-06	7.78e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CYP19A1—prostate cancer	5.95e-06	7.77e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—BAD—prostate cancer	5.94e-06	7.75e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—P4HB—prostate cancer	5.93e-06	7.74e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GGT1—prostate cancer	5.78e-06	7.54e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—SLC22A1—prostate cancer	5.77e-06	7.53e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—APC—prostate cancer	5.75e-06	7.5e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—PIK3CG—prostate cancer	5.75e-06	7.5e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—RXRA—prostate cancer	5.74e-06	7.49e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—NCOA1—prostate cancer	5.69e-06	7.43e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—EGF—prostate cancer	5.68e-06	7.42e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—IRS1—prostate cancer	5.68e-06	7.42e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—SULT2A1—prostate cancer	5.63e-06	7.34e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CYP19A1—prostate cancer	5.61e-06	7.32e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—MED12—prostate cancer	5.53e-06	7.22e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—COMT—prostate cancer	5.53e-06	7.22e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—GSK3B—prostate cancer	5.52e-06	7.2e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTP1—prostate cancer	5.51e-06	7.19e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GNG5—prostate cancer	5.49e-06	7.17e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—INS—prostate cancer	5.44e-06	7.1e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—ITPR1—prostate cancer	5.42e-06	7.07e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—RXRA—prostate cancer	5.41e-06	7.06e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CREBBP—prostate cancer	5.33e-06	6.96e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—NCOA3—prostate cancer	5.29e-06	6.9e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—IGF1—prostate cancer	5.27e-06	6.87e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—EGFR—prostate cancer	5.24e-06	6.84e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—COMT—prostate cancer	5.21e-06	6.8e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTP1—prostate cancer	5.19e-06	6.77e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—TYMS—prostate cancer	5.12e-06	6.68e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—ITPR1—prostate cancer	5.11e-06	6.66e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—MAP2K1—prostate cancer	5.09e-06	6.64e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTM1—prostate cancer	5.06e-06	6.6e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—PIK3CD—prostate cancer	5.06e-06	6.6e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—HPGDS—prostate cancer	5.05e-06	6.59e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYP2C19—prostate cancer	5.01e-06	6.54e-05	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—PIK3CA—prostate cancer	5.01e-06	6.53e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—SERPINE1—prostate cancer	5e-06	6.53e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—LPL—prostate cancer	4.97e-06	6.48e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—KRAS—prostate cancer	4.95e-06	6.46e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTT1—prostate cancer	4.89e-06	6.39e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—ACHE—prostate cancer	4.89e-06	6.39e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—FGF2—prostate cancer	4.84e-06	6.32e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYP2A6—prostate cancer	4.84e-06	6.31e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—TYMS—prostate cancer	4.82e-06	6.3e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CYP1A1—prostate cancer	4.8e-06	6.26e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—NOS3—prostate cancer	4.77e-06	6.23e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTM1—prostate cancer	4.77e-06	6.22e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—ERCC2—prostate cancer	4.76e-06	6.21e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—AKR1C3—prostate cancer	4.71e-06	6.14e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PRKACB—prostate cancer	4.68e-06	6.11e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—LPL—prostate cancer	4.68e-06	6.11e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—JAK2—prostate cancer	4.64e-06	6.05e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYP17A1—prostate cancer	4.63e-06	6.05e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—PIK3CA—prostate cancer	4.55e-06	5.93e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—MDM2—prostate cancer	4.53e-06	5.91e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CYP1A1—prostate cancer	4.52e-06	5.9e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—ERCC2—prostate cancer	4.48e-06	5.85e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—MTHFR—prostate cancer	4.47e-06	5.84e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—ERBB2—prostate cancer	4.47e-06	5.83e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—NCOA2—prostate cancer	4.41e-06	5.76e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—PIK3CB—prostate cancer	4.41e-06	5.75e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PPARA—prostate cancer	4.39e-06	5.73e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CXCL8—prostate cancer	4.23e-06	5.53e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—MTHFR—prostate cancer	4.21e-06	5.5e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—SLC5A5—prostate cancer	4.21e-06	5.5e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CDKN1B—prostate cancer	4.14e-06	5.4e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PPARA—prostate cancer	4.13e-06	5.4e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CAV1—prostate cancer	4.12e-06	5.38e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYP2E1—prostate cancer	4.11e-06	5.37e-05	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—AKT1—prostate cancer	4.09e-06	5.34e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—NQO1—prostate cancer	4.07e-06	5.31e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CASP3—prostate cancer	4.05e-06	5.29e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—IL2—prostate cancer	4.05e-06	5.28e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—IL6—prostate cancer	4.03e-06	5.25e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—TH—prostate cancer	4.01e-06	5.23e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CCND1—prostate cancer	3.94e-06	5.15e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CTNNB1—prostate cancer	3.91e-06	5.1e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYP1B1—prostate cancer	3.9e-06	5.09e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CAV1—prostate cancer	3.89e-06	5.07e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—MMP9—prostate cancer	3.83e-06	5e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CDKN1A—prostate cancer	3.82e-06	4.98e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—PTEN—prostate cancer	3.81e-06	4.97e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GGT1—prostate cancer	3.78e-06	4.93e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PIK3CG—prostate cancer	3.76e-06	4.9e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—NCOA1—prostate cancer	3.72e-06	4.85e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—AKT1—prostate cancer	3.71e-06	4.85e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYP19A1—prostate cancer	3.67e-06	4.78e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—EP300—prostate cancer	3.63e-06	4.74e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—INS—prostate cancer	3.56e-06	4.64e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PIK3CG—prostate cancer	3.54e-06	4.62e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—RXRA—prostate cancer	3.54e-06	4.62e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—SRC—prostate cancer	3.53e-06	4.61e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CREBBP—prostate cancer	3.48e-06	4.55e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—VEGFA—prostate cancer	3.44e-06	4.49e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—COMT—prostate cancer	3.41e-06	4.45e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—STAT3—prostate cancer	3.41e-06	4.44e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTP1—prostate cancer	3.39e-06	4.43e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—INS—prostate cancer	3.35e-06	4.37e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—ITPR1—prostate cancer	3.34e-06	4.36e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PIK3CD—prostate cancer	3.3e-06	4.31e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CREBBP—prostate cancer	3.28e-06	4.28e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—MYC—prostate cancer	3.16e-06	4.13e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—TGFB1—prostate cancer	3.16e-06	4.12e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—TYMS—prostate cancer	3.15e-06	4.12e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—NOS3—prostate cancer	3.12e-06	4.07e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTM1—prostate cancer	3.12e-06	4.07e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PIK3CD—prostate cancer	3.11e-06	4.06e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—EGFR—prostate cancer	3.09e-06	4.04e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—LPL—prostate cancer	3.06e-06	3.99e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.96e-06	3.86e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—NOS3—prostate cancer	2.94e-06	3.84e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—ERCC2—prostate cancer	2.93e-06	3.83e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—KRAS—prostate cancer	2.92e-06	3.82e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PIK3CB—prostate cancer	2.88e-06	3.76e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PTGS2—prostate cancer	2.85e-06	3.72e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—MTHFR—prostate cancer	2.76e-06	3.6e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PIK3CB—prostate cancer	2.71e-06	3.54e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PPARA—prostate cancer	2.7e-06	3.53e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PTGS2—prostate cancer	2.69e-06	3.51e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	2.69e-06	3.51e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—TP53—prostate cancer	2.6e-06	3.39e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CAV1—prostate cancer	2.54e-06	3.32e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PTEN—prostate cancer	2.49e-06	3.25e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—IL6—prostate cancer	2.38e-06	3.1e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—EP300—prostate cancer	2.37e-06	3.1e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PTEN—prostate cancer	2.34e-06	3.06e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.31e-06	3.02e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—EP300—prostate cancer	2.24e-06	2.92e-05	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—AKT1—prostate cancer	2.19e-06	2.86e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—INS—prostate cancer	2.19e-06	2.86e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CREBBP—prostate cancer	2.15e-06	2.8e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.03e-06	2.66e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—NOS3—prostate cancer	1.92e-06	2.51e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.77e-06	2.31e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PTGS2—prostate cancer	1.76e-06	2.29e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PIK3CA—prostate cancer	1.75e-06	2.29e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.65e-06	2.16e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PTEN—prostate cancer	1.53e-06	2e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—EP300—prostate cancer	1.46e-06	1.91e-05	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—AKT1—prostate cancer	1.43e-06	1.87e-05	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—AKT1—prostate cancer	1.35e-06	1.76e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.08e-06	1.41e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—AKT1—prostate cancer	8.83e-07	1.15e-05	CbGpPWpGaD
